Navigation Links
Kewaunee Scientific Corporation Declares Quarterly Dividend
Date:8/25/2010

STATESVILLE, N.C., Aug. 25 /PRNewswire-FirstCall/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU) announced today that its Board of Directors declared a quarterly cash dividend of ten cents per outstanding share, payable on September 23, 2010 to stockholders of record at the close of business on September 9, 2010.

Kewaunee Scientific Corporation is a recognized leader in the design, manufacture, and installation of scientific and technical furniture. The Company's corporate headquarters are located in Statesville, North Carolina.  The Company's manufacturing facilities are located in Statesville and Bangalore, India.  The Company has subsidiaries in Singapore and Bangalore, India that serve the Asian and Middle East markets.  Kewaunee Scientific's website is located at http://www.kewaunee.com.Contact:

D. Michael Parker704/871-3290
'/>"/>

SOURCE Kewaunee Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Kewaunee Scientific Reports Sales and Earnings for First Quarter
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
4. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
5. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
6. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
7. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
8. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
9. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
10. Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research
11. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... from the Company,s consumer product development program, based ... the Society for Investigative Dermatology (SID) 76 th ... advance and promote the sciences relevant to skin ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... , ... Sean Fay is the undisputed king of the infomercial. With clients ... George Foreman Grill (which sold more than 100 million units worldwide), he has created ... Now, due to changes in the broadcast media landscape, the once ever-present infomercial has ...
(Date:4/24/2017)... Florida (PRWEB) , ... April 24, 2017 , ... ... a variety of unique liquid food supplements, announced its popular products are now ... products. , ALP Nutrition® prioritizes the use of premium natural ingredients in ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... the telehealth industry, announces the company’s VideoMedicine mobile platform has launched Quick Care, ... 24 hours a day, Quick Care provides patients with the option to request ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, up to 78,000 ... 25,000 of them will be malignant.(1) As research into precision medicine continues, both ... model in the diagnosis and treatment of brain tumors. Healthcare facilities that are ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... health of individuals with HIV because it is not known to have significant ... have favorable effects to both lower cholesterol levels and dampen inflammation in the ...
Breaking Medicine News(10 mins):